Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, US FDA approves Genmab’s IND HuMax-CD4 to treat psoriasis19 Sept 2002
Genmab, Initial Accrual Complete in Genmab’s Humax-CD4 Phase II RA Study10 Sept 2002
Genmab, Genmab to Delist from the Regulated Market at the Frankfurt Stock Exchange10 Sept 2002
Genmab, over 60 % achieve ACR20 with Genmab´s HUMAX-IL154 Sept 2002
Genmab, timetable for Genmab's delisting from Neuer Markt of the Frankfurt Stock Exchange7 Aug 2002
Genmab, and Semaia Pharmaceuticals sign an alliance to develop antibodies against novel cancer targets31 Jul 2002
Genmab, Genmab applies to delist from the NEUER MARKT and the Frankfurt Stock Exchange26 Jul 2002
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
Genmab, Genmab’s Headquarters has moved to Toldbodgade 33 in Copenhagen
24 Jul 2002
Genmab, interim report 200215 Jul 2002
Genmab, announces financial results for the half year ended 30 June 200215 Jul 2002
Genmab, Genmab and JARI Pharmaceuticals BV to collaborate on research and development of antibody therapeutic products12 Jul 2002
Genmab, GENMAB HuMax-IL15 effective against psoriasis in mouse study1 Jul 2002
  • Previous
  • 1
  • More pages
  • 151
  • 152
  • 153
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863